Afzelin (Standard)

Afzelin (Standard) is the analytical standard of Afzelin. This product is intended for research and analytical applications. Afzelin (Kaempferol-3-O-rhamnoside) It is a flavonol glycoside that has anti-inflammatory, anti-oxidative stress response, anti-apoptotic, and anti-cardiac cytotoxic effects. AfzelinIt can reduce mitochondrial damage, enhance mitochondrial biosynthesis, and reduce mitochondria-related proteins. Parkinand PTENinduced putative kinase 1 (putative kinase 1) s level. AfzelinCan be improved D-galactosamine (GalN) /LPSSurvival rate of mice treated with doxorubicin prophylaxis (HY-15142A) Induced cardiotoxicity and scopolamine (HY-N0296) -induced neurological injury. AfzelinAlso inhibits asthma and allergies caused by ovalbumin[1][2][3][4].

Product Specifications

CAS Number

[482-39-3]

Product Name Alternative

Kaempferol-3-O-rhamnoside (Standard)

UNSPSC

12352005

Target

Autophagy; Bacterial; Mitochondrial Metabolism; PTEN; Reference Standards

Type

Reference Standards

Related Pathways

Anti-infection; Autophagy; Metabolic Enzyme/Protease; Others; PI3K/Akt/mTOR

Field of Research

Infection; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/afzelin-standard.html

Purity

99.44

Smiles

O=C1C(O[C@H]2[C@@H]([C@@H]([C@H]([C@H](C)O2)O)O)O)=C(C3=CC=C(O)C=C3)OC4=CC(O)=CC(O)=C14

Molecular Formula

C21H20O10

Molecular Weight

432.38

References & Citations

[1]Lee SB, et al. Afzelin ameliorates D-galactosamine and lipopolysaccharide-induced fulminant hepatic failure by modulating mitochondrial quality control and dynamics. Br J Pharmacol. 2017 Jan;174 (2) :195-209.|[2]Oh SY, et al. Central administration of afzelin extracted from Ribes fasciculatum improves cognitive and memory function in a mouse model of dementia. Sci Rep. 2021 Apr 28;11 (1) :9182.|[3]Zhou W, et al. Afzelin attenuates asthma phenotypes by downregulation of GATA3 in a murine model of asthma. Mol Med Rep. 2015 Jul;12 (1) :71-6.|[4]Sun Y, et al. Afzelin protects against doxorubicin-induced cardiotoxicity by promoting the AMPKα/SIRT1 signaling pathway. Toxicol Appl Pharmacol. 2023 Oct 15;477:116687.